Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.37 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.37 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 8/20 | 0.34 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2260920 | 0.75 | PDPK1 (0.41) | AXLMKNK1MKNK2PDPK1PARP1 | |
| SCHEMBL105581 | 0.74 | AXL (0.44) | AXLMKNK1MKNK2PDPK1PARP1 | |
| SCHEMBL29468124 | 0.74 | AXL (0.44) | AXLMKNK1MKNK2PDPK1PARP1 | |
| Hydrochloric Acid SCHEMBL4034218 | 0.73 | PDPK1 (0.40) | AXLMKNK1MKNK2PDPK1PARP1 | |
| SCHEMBL2799253 | 0.69 | HTR2C (0.60) | HTR2C | |
| SCHEMBL25202866 | 0.68 | ADORA2A (0.34) | AXLMKNK1MKNK2PDPK1PARP1 | |
| SCHEMBL953753 | 0.67 | KDR (0.42) | AXLMKNK1MKNK2PDPK1PARP1 | |
| SCHEMBL29367767 | 0.67 | KDR (0.42) | AXLMKNK1MKNK2PDPK1PARP1 | |
| SCHEMBL31324910 | 0.66 | AXL (0.44) | AXLMKNK1MKNK2PDPK1PARP1 | |
| SCHEMBL4037241 | 0.66 | AXL (0.44) | AXLMKNK1MKNK2PDPK1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050090483-A1 | Purine derivatives as kinase inhibitors | ELI LILLY AND COMPANY | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090483-A1 | Purine derivatives as kinase inhibitors | PNP, ADK, NME2 | AXL 908/4885MKNK1 312/4885MKNK2 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.